Successful treatment of tumor lysis syndrome associated with hepatic artery infusion chemotherapy in a patient with hepatocellular carcinoma: a case report.

Background: Tumor lysis syndrome is a life-threatening complication in the treatment of cancer. However, it rarely occurs in solid tumors, especially in hepatocellular carcinoma.

Case Presentation: We present a 52-year-old male Asian patient with advanced hepatocellular carcinoma treated with hepatic artery infusion chemotherapy that resulted in tumor lysis syndrome.

Risky Remedy: Rasburicase-Induced Methemoglobinemia in Tumor Lysis Syndrome Complicated by G6PD Deficiency.

Tumor lysis syndrome (TLS) is a critical oncologic emergency characterized by metabolic disturbances resulting from rapid cancer cell lysis. Rasburicase, a recombinant urate oxidase, is the primary treatment for hyperuricemia in TLS but poses a risk for methemoglobinemia in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency. We present the case of a 59-year-old male with diffuse large B-cell lymphoma (DLBCL) who developed spontaneous TLS.

Primary Oesophageal Lymphoma: A Diagnostic Dilemma.

Primary oesophageal lymphoma is an exceptionally rare cancer originating in the esophagus, distinct from more common oesophageal malignancies. Dawson's criteria has been the mainstay for diagnosis for such entities. However, recognizing primary oesophageal lymphoma is particularly challenging due to its rarity, diverse clinical presentations, and non-specific radiological and endoscopic features.

Effectiveness of rasburicase 4.5 mg in the treatment of tumor lysis syndrome-related hyperuricemia.

Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

Spontaneous Tumor Lysis Syndrome in an Undifferentiated Uterine Sarcoma: A Case Report and Review of the Literature.

Tumor lysis syndrome (TLS), as an oncologic emergency, may rarely occur in patients with solid organ neoplasms and without previous cancer therapy. Physicians should be highly aware of the possibility of TLS, with special attention in patients having bulky tumors, irrespective of recent treatment with cytotoxic agents for its prompt prevention and treatment.

Tumor Lysis Syndrome in a 30-Year-Old Male With Metastatic Seminoma: A Case Report.

A 30-year-old Hispanic male was admitted to the medicine service for a growing left testicular and pan-abdominal mass. His prior medical and surgical history was unremarkable. CT imaging showed a retroperitoneal and intraperitoneal mass.

Spontaneous Tumor Lysis Syndrome in a Thoracic Burkitt Lymphoma: A Case Report.

Burkitt lymphoma has a high proliferation rate and a significant risk of tumor lysis syndrome. Risk stratification and early identification are imperative since it is an oncological emergency. We report the case of a 20-year-old woman, without relevant past medical history, admitted to the Emergency Department with a three-week history of fatigue, chest discomfort, productive cough, night sweats, myalgia, odynophagia, and holocranial headache.

Successful management of type B lactic acidosis in metastatic cervical neuroendocrine carcinoma: A case report.

Type B lactic acidosis associated with malignancies is a rare but life-threatening complication, particularly in hematological cancers but less commonly in solid tumors. The current study presents a rare case of type B lactic acidosis in a 59-year-old woman with metastatic cervical neuroendocrine carcinoma (NEC), a highly malignant and uncommon tumor. The patient exhibited severe symptoms, including significant ascites, tachycardia and hyperlactatemia, with lactate levels peaking at 11.

Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study.

Background: Tarlatamab binds to delta-like ligand 3 on cancer cells and cluster of differentiation-3 on T cells, leading to T-cell-mediated tumor lysis, and has demonstrated a promising safety and efficacy profile in patients with previously treated small-cell lung cancer (SCLC). Here, we present pharmacokinetic results from DeLLphi-300 (NCT03319940), an ongoing international, open-label, first-in-human study in previously treated adult patients with SCLC.

Methods: Multiple escalating doses of tarlatamab were administered every 2 weeks (Q2W; 0.

Clinical and biological advances of critical complications in acute myeloid leukemia.

Managing acute myeloid leukemia (AML) and its critical complications requires understanding the complex interplay between disease biology, treatment strategies, and patient characteristics. Complications like sepsis, acute respiratory failure (ARF), hyperleukocytosis, coagulopathy, tumor lysis syndrome (TLS) and central nervous system (CNS) involvement present unique challenges needing precise evaluation and tailored interventions. Venetoclax-induced TLS and differentiation syndrome (DS) from IDH1/IDH2 or menin inhibitors highlight the need for ongoing research and innovative approaches.

Spontaneous tumour lysis syndrome in chronic lymphocytic leukaemia: an unanticipated complication of an undiagnosed disease.

Spontaneous tumour lysis syndrome (STLS) is a rare oncological emergency characterised by the spontaneous destruction of tumour cells in the absence of chemotherapy, with the release of large amounts of intracellular ions and metabolic products leading to organ damage and at times death. In chronic lymphocytic leukaemia (CLL), historically, tumour lysis syndrome has been rarely observed owing to low rate of proliferation and slow response to chemotherapy. We report a rare case of STLS in underlying undiagnosed CLL.

Enteral tube administration of extemporaneously compounded suspensions of venetoclax according to an institutional medication use process.

Introduction: Venetoclax is a potent oral oncology drug (OOD) frequently used to treat hematologic cancers due to its convenience and high efficacy. However, some patients cannot tolerate solid oral formulations, requiring a reformulated version of venetoclax for effective administration. Currently, there is limited information in the literature regarding the extemporaneous compounding of venetoclax.

Clinical Relevance of Intensive Laboratory Monitoring With Standard Venetoclax Ramp-Up for Chronic Lymphocytic Leukemia: A Real-World Experience.

Purpose: Venetoclax is the standard of care for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) but requires intensive monitoring for optimal safety. Clinical relevance of intensive monitoring in practice is unknown, especially for patients with low or intermediate risk for tumor lysis syndrome (TLS).

Patients And Methods: A retrospective review was conducted to determine clinical significance of monitoring for TLS during standard ramp-up for patients with CLL/SLL.